DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for stomach disease — screening already-approved drugs against its 32-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleStomach disease maps to a 32-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for stomach disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
protein tyrosine phosphatase non-receptor type 3 (PTPN3) — PTPN3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet dioxodrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4RI5 · 1.26 Å · ligand oxido(dioxo)vanadium (VN4). Experimental structure, not a prediction.
What the evidence adds up to
A 2017 meta-analysis pooled 2,205 cases and 2,289 controls from 12 case-control studies to assess whether IL-1β polymorphisms alter gastritis risk. The authors found that single nucleotide polymorphisms at IL-1β-31 (rs1143627) might be associated with gastritis risk, particularly in Caucasian populations, while IL-1β-511 (rs16944) showed no such association. The results were described as inconsistent and inconclusive across the original studies, and the meta-analysis itself did not establish a molecular mechanism, only a statistical link in a subgroup.
A 2014 case report describes one patient with gastroparesis refractory to conventional prokinetic treatment who showed rapid symptomatic and gastric-emptying improvement after receiving the antidepressant mirtazapine. This is a single case, with no control, no sample size, and no quantitative data on the degree of emptying improvement. A 2016 abstract on the granisetron transdermal system for gastroparesis mentions prokinetics including 5-HT4 agonists as having similar efficacy to metoclopramide in reducing nausea, but provides no trial results, response rates, or patient numbers. A 1977 case study of aversive behaviour therapy for chronic stomach pain reported that the treatment eliminated verbal report of pain, but the patient became increasingly depressed during the intervention, and only analytically oriented psychotherapy resolved that depression.
A 2014 review of portal hypertensive gastropathy states that no morphological change is considered pathognomonic, and that multiple mechanisms — endothelial dysfunction, apoptosis, damaging factors, and H. pylori infection — are involved to varying degrees. A 2022 study of 279 patients with H. pylori-associated stomach diseases concluded that the origin of various gastric diseases is closely related to the presence of the CagA gene in the bacterium, but the abstract gives no breakdown of disease types, outcomes, or effect sizes. Two 2024 review articles on pharmacotherapy for stomach disorders describe mechanisms of action and clinical applications for acid-related conditions, gastroparesis, and stomach cancer, but contain no original data.
What is missing is consistent evidence: no randomised controlled trials for mirtazapine or granisetron in gastroparesis, no prospective validation of IL-1β-31 as a risk marker, and no interventional data linking CagA status to treatment response. The case reports and meta-analyses are too small or too heterogeneous to guide therapy, and the reviews add no new numbers. Patient stratification by genotype, CagA status, or emptying rate, and adequately powered trials with objective endpoints, are still absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Medicine · 2017 · 15 citations · open access
Association between IL-1β polymorphisms and gastritis risk
AbstractBACKGROUND: Helicobacter pylori (H. pylori) infection of the human stomach regularly leads to chronic gastric inflammation. The cytokine gene interleukin (IL)-1β has been implicated in influencing the pathology of inflammation induced by H. pylori infection. Currently, several studies have been carried out to investigate the association of IL-1β-511 (rs16944) and IL-1β-31 (rs1143627) polymorphisms with gastritis risk; however, the results are inconsistent and inconclusive. To assess the effect of IL-1β polymorphisms on gastritis susceptibility, we conducted a meta-analysis. METHODS: Up to March 15, 2016, 2205 cases and 2289 controls were collected from 12 published case-control studies. Summarized odds ratios and corresponding 95% confidence intervals (CIs) for IL-1β-511 and IL-1β-31 polymorphisms and gastritis risk were estimated using fixed- or random-effects models when appropriate. Heterogeneity was assessed by chi-squared-based Q-statistic test, and the sources of heterogeneity were explored by subgroup analyses and logistic meta-regression analyses. Publication bias was evaluated by Begg funnel plot and Egger test. Sensitivity analyses were also performed. RESULTS: The results provided evidences that the single nucleotide polymorphisms (SNPs) in IL-1β-31 might be associated with the gastritis risk, especially in the Caucasian population, while SNPs in the IL-1β-511 might not be. CONCLUSION: Our studies may be helpful in supplementing the disease monitoring of gastritis in the future, and additional studies to determine the exact molecular mechanisms might inspire interventions to protect the susceptible subgroups.
Journal of Nippon Medical School · 2014 · 8 citations · open access
Successful Treatment of Gastroparesis with the Antidepressant Mirtazapine: A Case Report
AbstractTreatments for gastroparesis have been unsatisfactory. We describe a patient with gastroparesis who did not respond to a series of conventional prokinetic treatments. Finally, an antidepressant, mirtazapine, was administered, and the patient's symptoms and gastric emptying showed surprisingly rapid improvement. Therefore, we recommend mirtazapine as a treatment for gastroparesis refractory to conventional treatments.
Aversive behavior therapy for chronic stomach pain: A case study
AbstractA combined behavioral-psychodynamic treatment for severe, chronic stomach pain has been presented. In the case discussed, neither psychotherapy nor behavior therapy alone was successful in dealing with the patient's somatized depression. Aversive conditioning was credited with eliminating verbal report of pain and subjective sensation of chronic gastric pain. Simultaneous with the reduction in pain, however, the patient became increasingly depressed. Analytically oriented psychotherapy was instrumental in resolving the depression.
Russian Journal of Archive of Pathology · 2014 · 5 citations
Portal hypertensive gastropathy
AbstractIn spite of a great number of publications, as yet there is no agreement that which of the detected morphological changes should be considered pathognomonic in portal hypertensive gastropathy (PHG). The study of the pathogenesis of PHG suggested a diversity of mechanisms involved in varying degrees in the development of this abnormality. The paper summarizes the data available in the literature on the role of endothelial dysfunction, apoptosis, damaging factors, and H. pylori infection in the development of this abnormality. A differential diagnosis was made between PHG and GAVE syndrome and histological features in both groups were revealed.
Journal of Neurogastroenterology and Motility · 2016 · 1 citations · open access
Symptomatic Improvement of Gastroparesis with Granisetron Transdermal System
AbstractGastroparesis is a chronic relapsing condition that presents gastrointestinal (GI) symptoms related with delayed gastric emptying, that occurs in disorders such as diabetes mellitus, scleroderma, anorexia nervosa, Parkinson’s disease, and idiopathic.1 It includes nausea, vomiting, early satiation, postprandial fullness or epigastric pain. Prokinetics including serotonin receptor (eg, 5-HT4) agonists that stimulate gastric motor activity and show similar efficacy with metoclopramide in reducing nausea.2
Zenodo (CERN European Organization for Nuclear Research) · 2024 · 0 citations · open access
Etiology, causes, symptoms, diagnosis and treatment regarding Pharmacotherapy for Stomach Disorders
AbstractThe stomach, a key component of the digestive system, is prone to various disorders that can influence an individual's well-being in a significant manner. From acid-related conditions like gastritis and peptic ulcers to more complex issues such as gastro paresis and stomach cancer, effective pharmacotherapy plays an important role in managing these disorders. In this article, we will provide information regarding the treatment of stomach diseases in humans, highlighting their mechanisms of action as well as clinical applications.
Zenodo (CERN European Organization for Nuclear Research) · 2024 · 0 citations · open access
Etiology, causes, symptoms, diagnosis and treatment regarding Pharmacotherapy for Stomach Disorders
AbstractThe stomach, a key component of the digestive system, is prone to various disorders that can influence an individual's well-being in a significant manner. From acid-related conditions like gastritis and peptic ulcers to more complex issues such as gastro paresis and stomach cancer, effective pharmacotherapy plays an important role in managing these disorders. In this article, we will provide information regarding the treatment of stomach diseases in humans, highlighting their mechanisms of action as well as clinical applications.
Zenodo (CERN European Organization for Nuclear Research) · 2022 · 0 citations · open access
ROLE OF THE Ca g A GENE IN H.PYLORI-ASSOCIATED GASTRIC DISEASES
AbstractAbstract: The authors studied the epidemiological and molecular genetic characteristics of the bacterium in 279 patients with H. pylori-associated stomach diseases. The study is based on the results of endoscopic, molecular genetic research methods and statistical data. According to the study, the origin of various stomach diseases is closely related to the presence of the a gene. CagA in H. pylori.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works using Disease Ontology synonyms, resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
